17 April 2023
EMA/173420/2023
EMEA/H/C/002297

Public statement

Pioglitazone Teva

Withdrawal of the marketing authorisation in the European Union

On 31 March 2023, the European Commission withdrew the marketing authorisation for Pioglitazone Teva (pioglitazone) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Teva B.V., which notified the European Commission of its decision to permanently discontinue the marketing of the product for commercial reasons.

Pioglitazone Teva was granted marketing authorisation in the EU on 26 March 2012 for the treatment of type 2 diabetes mellitus. The marketing authorisation was initially valid for a 5-year period. It was then granted unlimited validity on 17 February 2017.

Pioglitazone Teva is a generic medicine of Actos, which is authorised and marketed in the EU to treat type 2 diabetes mellitus.

The European Public Assessment Report (EPAR) for Pioglitazone Teva will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union